Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (SNWV) pioneers noninvasive regenerative solutions through its proprietary PACE™ technology, advancing wound care and tissue repair innovations. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in developing FDA-cleared medical devices.
Access authoritative information about SNWV's technological advancements, including clinical trial outcomes, regulatory milestones, and strategic partnerships. Our curated collection features:
• FDA clearance announcements for new medical devices
• Clinical study results demonstrating treatment efficacy
• Financial performance updates and corporate developments
• Technology licensing agreements and partnership news
Bookmark this page for reliable updates on Sanuwave Health's progress in revolutionizing noninvasive therapies for wound management, orthopedic conditions, and aesthetic procedures. Verify all investment decisions against official SEC filings and consult medical professionals for clinical guidance.
SANUWAVE Health (OTCQB:SNWV) announced the issuance of 11 new patents, increasing its total to 150 active patents and applications. These patents enhance the company's proprietary shockwave and ultrasound technologies for medical and non-medical applications. Key patents include methods for tissue disinfection, clot treatment, and meat processing. The company continues to focus on developing its patented technologies and monetizing non-wound care applications. CEO Kevin Richardson highlighted that these patents strengthen SANUWAVE's competitive position in the advanced wound care market.
SANUWAVE Health (OTCQB:SNWV) has announced a $3 million private placement financing to enhance its growth initiatives in wound care products. The financing will occur in three tranches of $1 million and aims to strengthen the company’s balance sheet throughout 2021. CEO Kevin Richardson expressed optimism about the new capital allowing the company to advance its product offerings and improve wound care solutions. The company plans to file its third quarter 2020 Form 10-Q/A with the SEC soon, followed by its Annual Report on Form 10-K, with revenue guidance updates expected thereafter.
SANUWAVE Health (OTCQB: SNWV) has launched a comprehensive rebranding to enhance its advanced wound care offerings. The new brand identity highlights the integration of the dermaPACE® and UltraMIST® Systems, aligned with the company’s innovative "Energy First" protocol for wound healing. The acquisition of biologics, BIOVANCE® and Interfyl®, strengthens SANUWAVE’s product portfolio, aiming to optimize clinical outcomes. CEO Kevin A. Richardson, II, emphasizes the company’s commitment to providing effective, noninvasive treatment options for advanced wound care.
SANUWAVE Health (OTCQB: SNWV) announced its participation in several upcoming wound care conferences to promote its "Energy First" protocols. These events, both virtual and in-person, include the SuperBones SuperWounds East 2021 on April 17-18, AWCC in New Orleans on May 7, and others through June. SANUWAVE aims to educate industry specialists about its innovative wound care solutions, addressing chronic, non-healing wounds. CEO Kevin A. Richardson, II, emphasized the importance of showcasing their products and engaging with professionals at these conferences.
SANUWAVE Health, Inc. (OTCQB: SNWV) has established a non-exclusive sales and marketing agreement with Ametus to expand its wound care product portfolio in the U.S. This partnership aims to enhance SANUWAVE's market presence in underrepresented areas, leveraging Ametus' experienced sales force. Ametus specializes in advanced wound care and medical device products, covering significant portions of the western U.S. The company is known for its innovative energy-based technologies to address chronic wounds, improving healing processes and outcomes.
SANUWAVE Health, Inc. (OTCQB: SNWV) has announced a three-year exclusive distribution agreement with Kingdom Brother for its energy-based medical systems, including dermaPACE®, UltraMIST®, and WoundShield®, across several Southeast Asian countries. This region has the second highest diabetes prevalence (11.4%), presenting a significant market opportunity for wound care solutions. The agreement includes annual purchase commitments and a fixed transfer price, enhancing SANUWAVE's market presence and potential revenue growth.
SANUWAVE Health, Inc. (OTCQB: SNWV) has announced an exclusive distribution agreement with Labb Solutions for its dermaPACE® and UltraMIST® systems in Turkey and select countries in Eastern Europe and the Middle East. The first ten dermaPACE systems have already been shipped to Turkey. These energy-based medical systems aim to enhance wound care by leveraging innovative technologies. The dermaPACE system, FDA-cleared for diabetic foot ulcers, utilizes Pulsed Acoustic Cellular Expression (PACE®) technology. Meanwhile, UltraMIST offers non-contact ultrasound treatments to promote healing.
SANUWAVE Health, Inc. (OTCQB: SNWV) has signed a non-exclusive reseller agreement with DocShop Pro to market and sell its advanced wound care products, specifically the UltraMIST®, within the physician office channel. This agreement enhances SANUWAVE's commercial reach by utilizing DocShop Pro's 16-member sales team, facilitating access to innovative treatment options in podiatry. The partnership aims to leverage the average reimbursement of $417 per treatment for UltraMIST®, enhancing patient care and business growth.
SANUWAVE Health (OTCQB: SNWV) has formed a joint venture with MEDSTENT, S.A. to market its dermaPACE® System for treating chronic wounds in Mexico. This system, cleared by COFEPRIS, addresses diabetic foot ulcers, venous and arterial ulcers, and post-surgical wounds. The partnership aims to leverage MEDSTENT's expertise in the Mexican healthcare market to enhance access to this innovative treatment. The wound care market in Mexico is expected to grow at a CAGR of 6.72% over the next five years due to an aging population and increasing chronic wounds.
SANUWAVE Health, focused on advanced wound care, announced it will participate in significant medical meetings to showcase its Energy First approach with the dermaPACE® and UltraMIST® systems. Key events include DFCon20 (Oct 9-10), PRESENT e-Learning Systems (Oct 13), and The Academy of Physicians in Wound Healing Symposium (Oct 16-18). These platforms aim to educate specialists on innovative treatments for chronic wounds. The company's technologies enhance healing by combining energy transfer methods to improve patient outcomes.
